

## ORGANISATION

---

### Attendance Fee

750 € Regular

500 € Member of AGAH, EUFEMED

or Junior Scientist up to the age of 30

The participation fee is per person. Please note, according to §4 para 22 German turnover tax law, registration and workshop fees are exempt from VAT. Registration fees are charged and collected on behalf of AGAH e.V. All bookings are subject to change

**Registration Deadline: September 26, 2022**

### WORKSHOP VENUE

SocraTec R&D GmbH

Im Setzling 35

61440 Oberursel (Germany)

### REGISTRATION

**CSi Hamburg GmbH**

Goernestraße 30

20249 Hamburg (Germany)

Phone: +49 40 30770 300

e-Mail: [agah-meetings@csihamburg.de](mailto:agah-meetings@csihamburg.de)

### CONTACT

**Arbeitsgemeinschaft für angewandte  
Humanpharmakologie (AGAH) e.V.**

Office: Goernestraße 30

20249 Hamburg (Germany)

Phone: +49 40 30772097

e-Mail: [info@agah.eu](mailto:info@agah.eu)

Web: [www.agah.eu](http://www.agah.eu) · [www.studynurse.de](http://www.studynurse.de)

[Registration Link](https://forms.office.com/r/bvPwQaZ5Vh)

<https://forms.office.com/r/bvPwQaZ5Vh>

Programm subject to modifications, status July 2022

## CONTENT

---

### Pharmacokinetics – prerequisite and at the same time “door opener” for understanding pharmacology!

This workshop, developed by experienced specialists from industry, CRO and consultancy, offers an entrée to physiological background, measures and characteristics of pharmacokinetics. It helps to understand study design and evaluation of PK studies and the conclusions drawn from the results.

The workshop has been developed for clinical investigators, project leaders, project managers and monitors as well as PhD students in industry, hospitals, university and CROs. The knowledge obtained in this applied introductory course helps beginners in pharmacokinetics obtaining the basic knowledge and scientific background for professional handling, evaluation and interpretation of PK data.

### FACULTY

---

#### Dr. Stephan Glund

Head of Clinical Pharmacology CREA  
Boehringer Ingelheim Pharma GmbH & Co. KG  
Biberach (Germany)

#### Dr. Roland Heinig

Clinical Pharmacology  
Bayer AG, Pharmaceuticals  
Wuppertal (Germany)

#### Dr. Joachim Höchel

Clinical Pharmacology  
Bayer AG, Pharmaceuticals  
Berlin (Germany)

#### Dr. Frank Runge

Clinical Pharmacology Lead  
Boehringer Ingelheim Pharma GmbH & Co. KG  
Biberach (Germany)

#### Helmut Schütz

BEBAC – Consultancy Services for Bioequivalence and Bioavailability Studies  
Vienna (Austria)

#### Dr. Ralph-Steven Wedemeyer

Advisor Biopharmaceutics;  
Head of Pharmaceutical Technology  
SocraTec R&D GmbH  
Oberursel (Germany)



# AGAH

Arbeitsgemeinschaft  
für angewandte  
Humanpharmakologie e.V.

Association for Applied  
Human Pharmacology



**APPLIED COURSE  
INTRODUCTION INTO  
BASIC PRINCIPLES  
OF PHARMACOKINETICS**

**OCTOBER 6-7, 2022  
OBERURSEL (GERMANY)**

## PROGRAMME · DAY 1 · October 6, 2022

- 08:00 Registration
- 08:30 **Welcome and introduction** of participants and speakers  
*Joachim Höchel, Berlin; Barbara Schug, Oberursel*
- 08:45 **Human physiology: what you should know to better understand pharmacokinetics**  
An overview of physiological characteristics being of (PK)-relevance for **A**bsorption, **D**istribution, **M**etabolism and **E**limination (**ADME**)  
*Roland Heinig, Wuppertal*
- 09:30 **In vitro ADME & preclinical PK**  
Description of in vitro ADME parameters, such as Cytochrome P450 & drug transporter inhibition, drug absorption, plasma protein binding, and metabolic clearance; explanation of preclinical animal PK results and their translation to the human situation  
*Frank Runge, Biberach*
- 10:30 *Break*
- 10:45 **Discussion and Questions**
- 11:15 **How to measure what happens in pharmacokinetics: PK metrics of relevance!**  
An introduction into how one can quantify what the body does to the drug, i.e. which measures describe what happens to the drug including relevant methods of calculation  
*Helmut Schütz, Vienna*
- 12:00 *Break*
- 13:00 **Human PK studies I: bioequivalence, food interaction and drug-drug-interaction studies**  
Presentation of basic principles and design features such as choice of dosing, treatment and sampling schedule, evaluation approaches as well as population characteristics  
*Joachim Höchel, Berlin*

14:00 *Break*

## PROGRAMME · DAY 1 · October 6, 2022

- 14:15 **Human PK studies II: Special populations characteristics considering liver, kidney and age**  
Assessment of factors that relevantly impact PK in patients in adequately designed clinical trials considering authorities requirements  
*Roland Heinig, Wuppertal*
- 15:45 *Break*
- 16:00 **Hands-on clinical PK – the practical exercise:**  
How to design your PK program? An exercise with the goal to plan your own clinical PK program based on a preclinical data set  
*All*
- 17:30 **Discussion and Questions**
- 18:00 **End of Day 1 Workshop Program**
- 18:15 **Option of individual consultation of the speakers**  
Participants are invited to consult individual speakers if they have specific questions/case studies they wish to discuss with an expert.

## PROGRAMME · Day 2 October 7, 2022

- 08:30 **Introduction to biologics: what you should know to understand their pharmacokinetics**  
An overview of their molecular characteristics which interfere with pharmacokinetics – which types, characteristics and differences are of relevance  
*Stephan Glund, Biberach*
- 09:00 **Human PK – What's different in biologics?**  
An introduction into bioanalytical methods, antibody development and their assessment, specificities in ADME, TMDD, immunogenicity, drug-drug interaction and comparability  
*Stephan Glund, Biberach*
- 10:15 *Break*
- 10:30 **Human PK studies III: interplay between biopharmaceutics and absorption**  
What you should know about galenics and biopharmaceutics to understand the interplay between formulation principles and pharmacokinetics  
*Ralph-Steven Wedemeyer, Oberursel*
- 11:30 **Discussion and Questions**
- 12:00 *Break*
- 13:00 **Human PK studies IV: Human drug metabolism**  
How to determine the overall pathways of metabolism and excretion of an investigational drug and how to use these results in the context of drug safety (MIST, DDI).  
*Frank Runge, Biberach*
- 13:45 **Pitfalls in BA/BE**  
Attempts in beating Murphy's law: Learnings from failures in study design, bioanalytics and statistics  
*Helmut Schütz, Vienna*
- 14:30 *Break*
- 14:45 **Where all ends meet - PK information in the label**  
Review of a PK program – What, When, How – and Why?  
*All*
- 16:00 **End of Workshop**